Journey from Startup to Venture Capital and Longevity Investments

The chapter details the speaker's transition from startup companies to venture capital, their experience at TVM fund, involvement in investing in longevity-related projects, and the challenges and advancements in longevity research. It explores the concept of sirtuins, the complexity of targeting them for therapeutic purposes, and the evolving landscape of tools and regulatory frameworks in healthcare evaluation. The chapter also discusses the shift towards investing in longevity strategies in 2019, aiming for longer, healthier lives and promoting healthy aging by maintaining cellular systems to prevent age-related diseases.